Brown Melinda purchased $7K of DTIL

Precision BioSciences (DTIL) dosed the first patient in its Phase 1/2 FUNCTION-DMD trial for Duchenne muscular dystrophy (DMD). The trial evaluates PBGENE-DMD, a gene-editing therapy designed to restore near full-length dystrophin. Initial safety data is expected by year-end 2026. The study is enrolling patients aged 2-7 with specific DMD mutations.

Precision BioSciences (DTIL) reported a Q2 2026 net loss of $32.7M, an increase from the prior year. The company presented clinical data for PBGENE-HBV, showing cccDNA elimination in hepatitis B patients. PBGENE-DMD, for Duchenne muscular dystrophy, is advancing with initial safety data expected by year-end. Cash reserves total $112.4M, supporting operations through 2028.

iECURE, Inc. announced that data from its OTC-HOPE clinical trial of ECUR-506 for neonatal-onset OTC deficiency will be presented at the SSIEM Annual Symposium. The presentation will include safety and metabolic control data. iECURE is a clinical-stage genome editing company, and Precision BioSciences (DTIL) is involved through its ARCUS nuclease technology.

PRECISION BIOSCIENCES INC (DTIL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update - First clinical biopsy evidence of direct cccDNA elimination from ongoing Phase 1 ELIMINATE-B trial; PBGENE-HBV treatment led to a 1-log reduction in cccDNA with <1% rem

Precision BioSciences (DTIL) reported first clinical biopsy evidence from its ELIMINATE-B study that PBGENE-HBV can eliminate and inactivate hepatitis B cccDNA. The company said cccDNA transcripts fell 10-fold after two doses, with remaining cccDNA showing indels that disrupt viral polymerase. It also reported pgRNA as a biomarker and durable HBsAg declines up to a year; 38 doses in 16 patients showed no dose-limiting toxicities.

Conifer Management, L.L.C. purchased 273,712 indirectly-held shares of GROUP 1 AUTOMOTIVE INC (GPI) at an average of $242.15 ($235.63–$250.35, $66.28M total) across 29 trades over 2026-09-28 to 2026-09-30.